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With the development of systems biology, novel methods and techniques have emerged to help investigate complicated diseases. Metabonomics, as an important platform of systems biology, was defined originally as the quantitative measurement of the multiparametric response of living systems (8, 29) . The use of high-throughput analytical tools such as nuclear magnetic resonance, high-performance liquid chromatography in tandem with mass spectrometry, and gas chromatography in tandem with mass spectrometry, in combination with the multivariate data analysis method, can establish the variation of metabolic responses within biosamples. This technique has been applied successfully to the diagnosis of diseases (4, 51), evaluation of drug efficacy and toxicity (6, 13) , discovery of potential biomarkers (21) , and exploration of disease pathogenesis (30, 48, 50) . Recently, the metabonomics approach has been used to reveal the pathophysiological perturbations of atherosclerosis and to screen potential biomarkers involved in amino acid metabolism and fatty acid oxidation (3, 11, 47, 52) .
Recent advances in metabonomic technologies offer the possibility for evaluating potential posttranslational effects of D-4F on atherosclerosis. Because D-4F is a potent inhibitor of atherosclerosis, investigating D-4F-induced metabolic changes in an atherosclerosis model may not only help to understand how apolipoprotein A-I mimetic peptide inhibits atherosclerosis but will also help to evaluate the response to therapy. More importantly, such an investigation may yield new therapeutic targets or approaches. In the present study, we used the ultra-high-performance liquid chromatography in tandem with time-of-flight mass spectrometry (UPLC/TOF MS)-based metabonomics strategy to investigate and compare the metabolic parameters in the hypercholesterolemic LDLr Ϫ/Ϫ mice treated with or without D-4F as well as to identify significantly changed metabolites. Some significantly changed metabolites were confirmed with quantitative analysis using high-performance liquid chromatogram (HPLC)/TOF MS.
METHODS
Animal handling and sampling. All animal experiments were approved by The First Affiliated Hospital Review Board and Animal Research Committee at Sun Yat-sen University. Eight-week-old female LDLr Ϫ/Ϫ mice with a C57BL/6 background and female C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Female C57BL/6 mice were maintained on laboratory chow as the control group. LDLr Ϫ/Ϫ mice were fed a Western diet with or without D-4F peptide administered via intraperitoneal injection (1 mg·kg Ϫ1 ·day Ϫ1 ) or saline, as described before (33 
) was synthesized from D-amino acids by Sun Yat-sen University, as described previously (24, 33) .
Sample collection. Plasma anticoagulated with heparin was collected from all mice at the study end point. Plasma was separated at 4°C by centrifugation, then snap-frozen, and stored at Ϫ80°C until time of analysis.
Atherosclerotic lesion formation measurement. To measure atherosclerotic lesion formation, another set of mice was used (n ϭ 12). The whole aorta was isolated from mice and subsequently stained with sudan III. Atherosclerotic lesions were measured in en face preparations, as described elsewhere (25, 27) .
Sample preparation for metabolic profiling. Prior to analysis, the plasma samples were thawed at room temperature; 200 l of methanol was added to 50 l of plasma and vortex-mixed vigorously for 2 min. The mixture was centrifuged at 13,000 rpm for 15 min at 4°C. Every 200-l supernatant was pipetted out and diluted with 400-l of ultrapure water and then vortex-mixed. The solution was filtered through a 0.22-m filter film. The filtered solution was transferred to an injection vial and was subsequently analyzed by UPLC/TOF MS, as described previously (48) .
Chemicals. Formic acid and leucine enkephalin (HPLC grade) were purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile and methanol (HPLC grade) used for purposes of MS analysis were purchased from J. T. Baker (Phillipsburg, NJ). Ultrapure water (18.2 M⍀) was prepared using a Milli-Q water purification system (Millipore). 1-hexadecanoyl-sn-glycero-3-phosphocholine[LysoPC(16:0)], 1-O-1=-(Z)-octadecenyl-2-hydroxy-sn-glycero-3-phosphoethanolamine[C18(Plasm) LysoPE], 1,2-distearoyl-sn-glycero-3-phosphocholine[PC(18:0)(DSPC)], and 1-2-dioleoyl-sn-glycerol[DG(18:1)], which were purchased from Avanti Polar Lipids (Alabaster, AL), were used as standards for quantitative analysis.
UPLC conditions. Chromatographic separation was performed on a 100 ϫ 2.1 mm ACQUITY BEH 1.7-m C 18 column, using an ACQUITY UPLC system (Waters). The column temperature was set to 50°C, whereas the flow rate was set at 0.4 ml/min. The autosampler was maintained at 4°C. The mobile phases consisted of ultrapure water with 0.1% formic acid (phase A) and acetonitrile (phase B). A linear gradient elution of 5-50% phase B was applied from 0 to 3 min, followed by a further linear increase to 95% phase B over the next 17 min. The eluent was then held constant for 2 min, after which it was returned to 5% phase B for 1 min. Before the next injection, this eluent was equilibrated for 5 min. For each analysis, 5 l of the sample was injected on to the column.
MS conditions. Mass spectrometry was performed using a TOF MS (W mode of operation; Waters) operating in the positive ion and negative ion electrospray mode. The data were collected from massto-charge ratio (m/z) 100 to m/z 1,000. The capillary voltage was set to 2,300 V for the positive mode and 2,500 V for the negative mode. Cone voltage was 35 V. Nitrogen was used as the drying gas. The cone gas flow rate was set to 40 l/h, and the desolvation gas flow rate was maintained at 700 l/h. The desolvation temperature was set to 350°C, and the source temperature was 120°C. The scan time and iner-scan delay were set to 0.1 and 0.02 s, respectively. All analyses were completed using an independent reference lock-mass ion via the LockSpray interface to ensure accuracy and reproducibility. Leucineenkaphalin was used as the reference compound ([M ϩ H] ϩ ϭ 556.2771 and [M ϩ H] Ϫ ϭ 554.2615) at a concentration of 50 pg/l and flow rate of 10 l/min. The data were collected in the centroid mode, with the LockSpray frequency set at 10 s and averaged over 10 scans for correction purposes.
It is important to optimize both UPLC and MS conditions for applications. The parameters, such as the proportion of mobile phase, flow rate, elution gradient collision energy, capillary voltage, cone voltage, desolvation temperature, and nitrogen pressure, were optimized in both positive and negative ion mode.
Data processing. The raw spectrometric data were processed by MarkerLynx Applications Manager version 4.1, which incorporates an ApexTrack peak to detect chromatographic peaks (Waters). The track peak parameters were set as follows: peak width at 5% height for 15 s, peak-to-peak baseline noise 80, intensity threshold of 100, mass window of 0.05 amu, retention time window of 0.2 min, noise elimination level of 6, and mass tolerance of 0.50 amu. The individual intensity was normalized to the sum of all the peak intensities by Markerlynx. These normalized data were further processed by Simca P version 12.0 (Umetrics) for multivariate data analysis. Basic applications, such as principal component analysis (PCA), partial leastsquares discriminate analysis (PLS-DA), and orthogonal signal correction partial least-squares discriminate analysis (OPLS-DA), were implemented.
Identification of significantly changed metabolites. Significantly changed metabolites can be selected according to the value of variable importance for projection (VIP), which explains the contribution of an ion to different models, such as PLS-DA and OPLS-DA (18) . In this study, PLS-DA models were constructed on the basis of plasma metabolic profiling, and the metabolites were selected as significantly changed metabolites according to a variable importance for projection value of Ͼ1 and a significance level of P Ͻ 0.05.
Identification of significantly changed metabolites was based on their exact mass measured via UPLC/TOF MS, which was obtained from isotopic patterns and metabolite databases (44, 49) . The MS data were processed by Masslynx, which provided the elemental compositions. The mass error window was set at 10 mDa; simultaneously, the i-fit value was taken into consideration, which provides a value for isotope-fitting pattern with a lower i-fit value, suggesting a better fit. Calculated elemental compositions will be used to query chemical and biochemical databases. Current metabolite databases such as the Kyoto Encyclopedia of Genes and Genomes Ligand Database (http:// www.genome.jp) and the Human Metabolome Database (http:// www.hmdb.ca) were used to search for candidate molecules (17) .
As an example of this process, what follows is a description of the identification process of LysoPC (18:3). First, an ion peak m/z 562.315 was found in spectrum under negative mode. Using the elemental composition tool, C27H50NO9P was located as the candidate. Then it was input into Human Metabolome Database for possible compound. The search result showed that the ion of m/z 562.315 was [M ϩ FA-H] Ϫ for C26H48NO7P. Finally, considering the high mass accuracy and low i-fit value, LysoPC (18:3) was identified as a significant change metabolite.
Quantitative analysis of phospholipids. We have developed a rapid and specific analytical method for simultaneous determination of some major phospholipid classes by HPLC/TOF MS and validated it with satisfied recovery, precision, and accuracy (35) . For quantitative analysis of phospholipids in this study, the experimental procedures, including plasma sample preparation, chromatographic separation, and TOF MS-based detection, were essentially the same as described earlier (35) . Considering the target analytes and their content range in this study, a series of standard working solutions with the concentrations of 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 g/ml for LysoPC (16:0) and DG (18:1) and 1, 2, 3, 4, 5, 10, 20, 30, 40, and 50 g/ml for LysoPE (18:0) and PC (18:0) was used for calibrations.
Statistical analysis. Differences among test groups were analyzed by ANOVA, followed by the Newman-Keuls test for multiple comparison (Prism 4.0; GraphPad Software, San Diego, CA). A P value of Ͻ0.05 was considered statistically significant.
RESULTS

Atherosclerotic lesion formation.
To confirm the effect of D-4F on the pathogenesis of atherosclerosis, the lesion formations within the aortas of mice were measured. As shown in Fig. 1, A and B, atherosclerotic lesions were apparent in LDLr Ϫ/Ϫ mice that were fed a Western diet for 10 wk. Additionally, D-4F significantly reduced the aortic lesions in hypercholesteromic LDLr Ϫ/Ϫ mice in a time-dependent manner.
Chromatograms of the plasma or D-4F peptide analyzed by UPLC/TOF MS.
A metabonomic study based on UPLC/TOF MS was applied to investigate the metabolic profiles of the different groups. A typical plasma base peak chromatogram operating under positive and negative ion mode is illustrated in Fig. 2 , A and B, respectively. As clearly illustrated, thousands of ion peaks were detected in both ionization modes. Since D-4F does not degrade in vivo, it can also be detected in the plasma of treated mice in the form of the [M Ϫ H] Ϫ m/z 1,154 ion (Fig. 2, C-E) . Because the metabolic changes of D-4F itself were not a primary concern in the present study, the [M Ϫ H] Ϫ m/z 1,154 ion was excluded from detection to eliminate the influence of D-4F in data analysis. The mass data were collected from m/z 100 to m/z 1,000 since the m/z of most endogenous metabolites is Ͻ1,000.
Pattern recognition analysis of metabolic profiling. Both unsupervised (e.g., PCA) and supervised strategies (e.g., PLS-DA, OPLS-DA, etc.) are employed for multivariate statistics and model building for prediction and classification of outcomes in metabonomic studies, as described previously (15) . In the positive ion mode, PCA was first performed to find out the metabolic difference between hypercholesterolemic LDLr Ϫ/Ϫ mice and C57BL/6 mice and to investigate the effect of D-4F. As shown in Fig. 3A , the metabolic pattern was different To further understand the difference of metabolic profiles between the groups, PLS-DA was applied. Figure 3B shows a clear discrimination in the scores of the PLS-DA model between the different groups. Because OPLS-DA is the most advanced development in PLS-DA, this technique was also performed to further improve interpretation. As shown in Fig.  3C , the scores plot of OPLS-DA was similar to that of PLS-DA. The trajectory of metabolic perturbation in Fig. 3 , A-C, indicates a time-dependent effect of D-4F on the metabolic profile of the hypercholesterolemic LDLr Ϫ/Ϫ mice. Indeed, as illustrated in the three-dimensional scores plot (Fig. 3G) , D-4F treatment of the hypercholesterolemic LDLr Ϫ/Ϫ mice resulted in metabolic profiles similar to that of the C57BL/6 mice.
To further investigate the changes in response to different time treatments with D-4F, PLS-DA models of groups 3-5 were compared with groups 1 and 2. Three PLS-DA score plots were showed in Fig. 3, D (groups 1-3 ), E (groups 1, 2, and 4), and F (groups 1, 2, and 5). As shown in Fig. 3 , D-F, marked differences in metabolic patterns were observed among the hypercholesterolemic LDLr Ϫ/Ϫ mice, the control group, and the D-4F treatment groups, suggesting that D-4F significantly altered plasma metabolic status of hypercholesterolemia.
Metabolic profiling data acquired in negative ion mode was also analyzed by PCA, PLS-DA, and OPLS-DA. As shown in Fig. 4 , the results were similar to those described above for the positive mode. Indeed, significant differences in metabolic profiles were observed between the hypercholesterolemic LDLr Ϫ/Ϫ mice, the D-4F-treated mice, and the C57BL/6 mice. Screening and identification of significant change metabolites. According to the PLS-DA analysis of plasma metabolic profiling, 36 significantly changed metabolites were identified (listed in Table 1 ). Among these metabolites, six categories were identified in both positive and negative ion mode, including LysoPC, lysophosphatidylethanolamine (LysoPE), phosphatidylcholine (PC), phatidylethanolamine (PE), sphingomyelin (SM), and diacylglycerol (DG). The majority of the identified metabolites were phospholipids with long-chain acyl groups (C Ն 18), with LysoPC being the major phospholipid category, which includes 15 different acyl chain LysoPC.
To investigate the specific change of the metabolites in plasma, the relative contents of significantly changed metabolites were calculated according to their average peak intensity in each group. The ion intensities for each detected peak were normalized against the sum of the peak intensities with that sample using MarkerLynx. Ions of different samples were considered to be the same ion when they demonstrated the same t R (tolerance of 0.01 min) and m/s value (tolerance of 0.01 Da). If a peak was not detected in a sample, the ion intensity was documented as zero in the table. We compared 14 significantly changed metabolites at a significance level of P Ͻ 0.01 (Fig. 5) . The results showed that levels of these significantly changed metabolites, including LysoPC, LysoPE, PE, PC, DG, and SM, were dramatically elevated in hypercholesterolemic LDLr Ϫ/Ϫ mice. Furthermore, most of them, including four different acyl chain LysoPC, were reduced by D-4F in a time-dependent manner.
Quantification of phospholipids in plasma. Considering the commercial availability of reference standards and the principle of similarity, phospholipids LysoPE (18:0), LysoPC (16:0), PC (18:0), and DG(18:1) were selected as calibration standards for quantification of the representative phospholipids of interest. Because phospholipids species within the same phospholipid class have similar structures and similar signal responses, the same phospholipid class can be quantified according to the calibration curves of those commercial phospholipids (35) . Using this method, the target phospholipids in plasma were separated well (Fig. 6) , and the calibration correlation coefficients were Ͼ0.99 (Table 2 ). These quantitative results are more accurate for estimating the variation of phospholipid metabolites than using the ion intensities in plasma metabolic profiling. The concentrations of some representative phospholipids in different groups are shown in Table 3 and are essentially consistent with the findings in Fig. 5 .
DISCUSSION
D-4F partially shifted the metabolic profiles of hypercholesterolemia back to normal.
Previous studies have shown that the metabolic profiles of individuals with certain types of diseases, including coronary artery disease and diabetes, are significantly different from those of healthy individuals (4, 19, 40, 41, 45) . We and others have previously used the novel approach of metabonomics to study the pathogenesis of various conditions as well as to evaluate drug efficacy (4, 6, 21, 30, 43, 48) . In the present study, this is the first time that the metabonomics technique has been used to investigate the effect of the apolipoprotein A-I mimetic peptide D-4F on hypercholesterolemia and atherosclerosis. We found a distinct difference between the metabolic profiles of hypercholesterolemic LDLr Ϫ/Ϫ and C57BL/6 mice, suggesting that plasma metabolites are distinct in quantity and/or quality between the hypercholesterolemic LDLr Ϫ/Ϫ mice and C57BL/6 mice. More importantly, the metabolic clustering of hypercholesterolemic LDLr Ϫ/Ϫ mice treated with D-4F was distinct from untreated mice but close to that of C57BL/6 mice. These data demonstrated that D-4F could partially shift the metabolic trajectory of hypercholesterolemic LDLr Ϫ/Ϫ mice back to C57BL/6 mice with a timedependent effect. Because our atherosclerotic lesion data and a previous report showed that D-4F dramatically inhibited atherosclerosis (24) and that D-4F partially altered the metabolic profiles, our findings suggest that D-4F can significantly inhibit atherosclerosis in part by regulating the metabolism of hypercholesterolemic LDLr Ϫ/Ϫ mice. Additionally, we found previously that D-4F afforded greater vascular protection in hypercholesterolemia in vivo than in vitro (32) . Given that D-4F may alter the metabolism of hypercholesterolemic LDLr Ϫ/Ϫ mice, it is possible that D-4F may achieve maximal vascular protection by regulating plasma metabolites.
D-4F reduced phospholipid metabolites in hypercholesterolemia. Through discovery-based metabonomic experiments, we processed metabolic fingerprints using multivariate data analysis and screened out 36 significantly altered metabolites, most of which were phospholipids, including LysoPC, LysoPE, PC, PE, SM, and DG. Among these phospholipids, the majority were phospholipids with long-chain acyl groups (i.e., C Ն 16), particularly long-chain LysoPC. We then estimated their relative amounts on the basis on their ion intensities in the metabolic profiles and determined 14 metabolites that reached a significance level of P Ͻ 0.01. All of the 14 metabolites identified were phospholipids, and the majority of these metabolites were increased in the hypercholesterolemic state and reduced with D-4F treatment. To validate these findings, several phospholipid metabolites were quantified via an external calibration method. As shown in Table 3 Previous studies have demonstrated that D-4F can separate cholesterol from phospholipids and remove oxidized lipids from lipoproteins (26, 28) . D-4F appeared to be the most effective analog in binding and removing oxidized lipids compared with other 4F and 2F analogs, which do not inhibit atherosclerosis (2, 7, 22, 26) . Thus, it is possible that D-4F may bind and solubilize phospholipids, especially long-chain LysoPC, to reduce their plasma concentrations. Whether D-4F also reduces such phospholipid levels in chow diet LDLr Ϫ/Ϫ mice needs to be determined in future studies.
Reduction of plasma long-chain LysoPC may be one of the major reasons for D-4F inhibited atherosclerosis. In the present study, we found that LysoPCs, especially long-chain LysoPCs, are the most significantly affected metabolites in hypercholesterolemia and following D-4F treatment. Both Fig.  5 and Table 3 reveal that the relative amounts of LysoPC (20:2), LysoPC (20:3), and LysoPC (20:4) are much greater than those of LysoPC (18:3) in hypercholesterolemia. These data suggest that LysoPCs with longer long-chain acyl groups (i.e., C ϭ 20) are relatively more abundant than LysoPCs (18:3). More importantly, all of these LysoPCs were reduced with D-4F treatment, especially LysoPCs (18:3) . Previous reports demonstrated that LysoPC is a proinflammatory lipid that plays an important role in atherosclerosis and inflammatory diseases by altering various functions in a number of cell types, including endothelial cells, smooth muscle cells, monocytes, macrophages, and T cells (1, 9, 10, 22 ). LysoPC is a major atherogenic component of oxidized LDL that is responsible for the reduced vasodilation observed in atherosclerosis (12) . It has been reported previously that plasma LysoPC levels are significantly elevated in atherosclerotic patients (39) and that LysoPC is an important biomarker of coronary artery disease (14) . However, Plane et al. (37) found that the ability of LysoPC to impair vasodilation did not correlate with the concentration of LysoPC present. Indeed, Liu et al. (16) demonstrated that the proportion of LysoPC, and not the actual LysoPC concentration, affects vasodilation. Chen et al. (5) further found that LysoPC with long-chain acyl groups (i.e., C Ͼ 16) were more effective in impairing vasodilation. Thus, long-chain LysoPC may be one of the major elements in LDL that causes atherosclerosis and endothelial dysfunction (5, 22) . We found that D-4F treatment reduced the amount of circulating long-chain LysoPC. These findings suggest that D-4F may also decrease LysoPC within LDL particles and thereby reduce Rt/min, retention time in the chromatogram per minute; m/z, Mass-to-charge ratio; DG, diacylglycerol; LysoPC, lysophosphatidylcholine; LysoPE, lysophosphatidylethanolamine; MG, monoacylglycerol; PC, phosphatidylcholine; PE, phatidylethanolamine; SM, sphingomyelin; VPGPR, Val-Pro-Gly-ProArg. Thirty-six potential biomarkers were selected according to the value of variable importance for projection. The identification of the potential biomarkers was based on their exact mass, as obtained via ultra-high-performance liquid chromatography in tandem with with time-of-flight mass spectrometry (HPLC/TOF MS), considering isotopic patterns and metabolite database. the inflammatory nature of LDL. Furthermore, a previous study by Pruzanski et al. (38) demonstrated that proinflammatory HDLs contain more LysoPCs than normal HDLs. Thus, the D-4F-induced decrease in circulating LysoPC may also reduce the amount of LysoPC within HDL particles and thereby improve HDL function. However, future studies that compare LysoPC levels within HDL particles with and without D-4F treatment are warranted to further clarify these issues. Taken together, our data suggest that the reduction in plamsa longchain LysoPCs may be one of the major reasons for the D-4F-induced inhibition of atherosclerosis and improved vasodilation. Despite the fact that D-4F can activate lecithin cholesterol acyltransferase activity (2, 26) and that circulating LysoPCs are generated predominantly via a reaction induced by lecithin cholesterol acyltransferase (42) , our data demonstrated that LysoPC levels were decreased rather than increased. These observations suggest that D-4F may bind and remove LysoPC to reduce its concentration.
D-4F decreased other metabolites in hypercholesterolemia. PC was another significantly affected metabolite in the present study. Since LysoPCs are generated from PC (22), a D-4F-induce reduction in circulating PC may also contribute to the http://ajpendo.physiology.org/ decrease in LysoPC. Conversely, PE was increased in hypercholesterolemia and increased even more following a shortterm D-4F treatment. However, long-term D-4F treatment decreased plasma PE significantly. It has been reported previously that PE can be converted into PC (20) . Thus, the D-4F-induced reduction in PE may result from a reduction in PC and LysoPC levels. Furthermore, a previous study demonstrated that plasma SM concentrations correlate with the development of atherosclerosis and that SM is an independent predictor of coronary artery disease and a novel biomarker for atherosclerosis (36) . In the present study, we found that D-4F also reduced SM in a time-dependent fashion (Fig. 5) . Thus, taken together, our findings suggest that D-4F may inhibit atherosclerosis in part by reducing various kinds of phospholipids, especially long-chain LysoPCs.
Interestingly, one of the identified metabolites within the present study was DG. One report suggested previously that dietary DG induces a regression in atherosclerosis (31) . Conversely, our data suggest that DG is increased significantly in hypercholesterolemia and reduced with D-4F treatment. Despite the fact that D-4F reduced DG, as mentioned above, D-4F also deceased many other atherogenic phospholipids, which may in the end inhibit atherosclerosis.
There were other metabolites identified in the present study, but their role in atherosclerosis and vascular function is presently unclear. These metabolites include Val-Pro-Gly-Pro-Arg enterostatin, proline betaine, monoacylglycerol, 3-hexaprenyl-4-hydroxybenzoic acid, and cis-5,6-dihydro-5,6-dihydroxycarotene. Furthermore, some of the significantly altered metabolites were unidentifiable. For example, C6H14O6 (M Ϫ H [1Ϫ]) could be either melibiose, galactinol, trehalose, or some other metabolite, and C12H22O11 (M ϩ H [1ϩ]), could either be mannitol, sorbitol, galactitol, L-iditol, or some other metabolite. It should be noted that the metabolism status may have some differences among different sexes. To eliminate the basic diversity among the groups, we used the same batch of the female mice that grew in the same living environment in this study, and thus the metabolism status was similar. It will also be important to repeat the study with male mice in the future.
In summary, our findings suggest that the metabolic status of hypercholesterolemic mice is distinct from normal mice, which is due largely, in part, to differences in plasma phospholipid levels of LysoPC, LysoPE, PC, PE, SM, DG, and, in particular, long-chain LysoPC (i.e., C Ն 16). Treatment with D-4F can shift the hypercholesterolemic metabolism in a time-dependent manner toward the metabolism of the healthy control group. Thus, D-4F may inhibit atherosclerosis in part by decreasing plasma phospholipids, especially long-chain LysoPCs. Furthermore, long-chain LysoPC may be used as a potential diagnostic biomarker for atherosclerosis. 
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